Back to top
more

ANI Pharmaceuticals (ANIP)

(Real Time Quote from BATS)

$65.05 USD

65.05
10,606

-1.69 (-2.53%)

Updated Jun 10, 2024 10:12 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Compared to Estimates, ANI (ANIP) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for ANI (ANIP) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Lumos Pharma (LUMO) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Lumos (LUMO) delivered earnings and revenue surprises of 5.45% and 96.22%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Poseida Therapeutics, Inc. (PSTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Poseida Therapeutics, Inc. (PSTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ANI Pharmaceuticals (ANIP) Stock Drops Despite Market Gains: Important Facts to Note

by Zacks Equity Research

ANI Pharmaceuticals (ANIP) closed at $61.66 in the latest trading session, marking a -0.13% move from the prior day.

ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amgen (AMGN) Q3 Earnings Top Estimates

by Zacks Equity Research

Amgen (AMGN) delivered earnings and revenue surprises of 6.67% and 0.80%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

ANI Pharmaceuticals (ANIP) Increases Despite Market Slip: Here's What You Need to Know

by Zacks Equity Research

ANI Pharmaceuticals (ANIP) closed at $57.44 in the latest trading session, marking a +0.23% move from the prior day.

ANI Pharmaceuticals (ANIP) Stock Moves -0.14%: What You Should Know

by Zacks Equity Research

The latest trading day saw ANI Pharmaceuticals (ANIP) settling at $57.31, representing a -0.14% change from its previous close.

ANI Pharmaceuticals (ANIP) Stock Moves -0.48%: What You Should Know

by Zacks Equity Research

In the most recent trading session, ANI Pharmaceuticals (ANIP) closed at $57.66, indicating a -0.48% shift from the previous trading day.

ANI Pharmaceuticals (ANIP) Stock Sinks As Market Gains: Here's Why

by Zacks Equity Research

The latest trading day saw ANI Pharmaceuticals (ANIP) settling at $58.39, representing a -0.41% change from its previous close.

(ANIP) Advances While Market Declines: Some Information for Investors

by Zacks Equity Research

In the most recent trading session, ANI Pharmaceuticals (ANIP) closed at $58.63, indicating a +1.98% shift from the previous trading day.

ANI Pharmaceuticals (ANIP) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

ANI Pharmaceuticals (ANIP) closed at $58.06 in the latest trading session, marking a -1.41% move from the prior day.

Mirati (MRTX) Soars 12.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Mirati (MRTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

ANI Pharmaceuticals (ANIP) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

ANI Pharmaceuticals (ANIP) closed the most recent trading day at $59.33, moving -1.98% from the previous trading session.

ANI Pharmaceuticals (ANIP) Stock Moves -0.9%: What You Should Know

by Zacks Equity Research

ANI Pharmaceuticals (ANIP) closed at $60.53 in the latest trading session, marking a -0.9% move from the prior day.

Elutias (ELUT) Up on Sale of Orthobiologics Business for $35M

by Zacks Equity Research

Elutias (ELUT) gains on divestiture of Orthobiologics business unit for $35 million to Berkeley Biologics LLC, a wholly-owned subsidiary of GNI Group Ltd.

PTC Therapeutics (PTCT) Down on Negative CHMP Opinion for DMD Drug

by Zacks Equity Research

PTC Therapeutics (PTCT) plunges on negative opinion from the Committee for Medicinal Products for Human Use for conditional marketing and full marketing authorization of Translarna (ataluren) to treat nonsense mutation Duchenne muscular dystrophy.

ANI Pharmaceuticals (ANIP) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, ANI Pharmaceuticals (ANIP) closed at $63.61, marking a +1.26% move from the previous day.

UnitedHealth Group (UNH) Wins Medicaid Deal to Help Serve Texas

by Zacks Equity Research

UnitedHealth Group (UNH) unit has been awarded a contract by the Texas Health and Human Services Commission to better cater to the statewide Medicaid members.

Here's Why You Should Add ANI Pharmaceuticals (ANIP) to Your Portfolio

by Zacks Equity Research

ANI Pharmaceuticals (ANIP), a top-ranked stock, has a diverse portfolio of rare disease and generic medicines. Its Purified Cortrophin Gel is witnessing incremental sales in recent quarters.

ANI (ANIP) Is a Great Choice for 'Trend' Investors, Here's Why

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, ANI (ANIP) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Lisata (LSTA) Up on Positive Updates for Pancreatic Cancer Study

by Zacks Equity Research

Lisata's (LSTA) shares gain on a favorable outcome in interim futility analysis of its lead candidate, LSTA1, for pancreatic cancer.

Palisade (PALI) In-Licenses Rights for IBD Candidate, Stock Up

by Zacks Equity Research

Palisade (PALI) gains on entering into global licensing deal with Giiant Pharma to develop gastrointestinal therapies.

Ensign Group (ENSG) Pursues Facility Buyouts in South Carolina

by Zacks Equity Research

Ensign Group (ENSG) acquires two skilled nursing facilities in South Carolina to offer enhanced healthcare services to the state's residents.

Insmed (INSM) Up on Positive Data From MAC Lung Disease Study

by Zacks Equity Research

Insmed's (INSM) shares rise on positive data from the late-stage ARISE study evaluating Arikayce for newly infected lung disease caused by MAC.